RT Journal Article
SR Electronic
T1 Clinical Verification on the Predictors for Febrile Neutropenia in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 247
OP 254
DO 10.21873/anticanres.16156
VO 43
IS 1
A1 GOTO, WATARU
A1 KASHIWAGI, SHINICHIRO
A1 MATSUOKA, KOHEI
A1 IIMORI, NOZOMI
A1 KOUHASHI, RIKA
A1 YABUMOTO, AKIMICHI
A1 TAKADA, KOJI
A1 ASANO, YUKA
A1 TAUCHI, YUKIE
A1 OGISAWA, KANA
A1 MORISAKI, TAMAMI
A1 SHIBUTANI, MASATSUNE
A1 TANAKA, HIROAKI
A1 MAEDA, KIYOSHI
YR 2023
UL http://ar.iiarjournals.org/content/43/1/247.abstract
AB Background/Aim: Febrile neutropenia (FN) is a potentially life-threatening complication of chemotherapy. In this study, we evaluated the predictors for FN according to neoadjuvant chemotherapy (NAC) in all breast cancer subtypes. Patients and Methods: We examined 327 patients with breast cancer treated with NAC. The correlation between the development of FN and clinicopathological features, including systemic inflammatory markers, and prognosis was evaluated retrospectively. Results: There were no significant differences between patients with and without FN in terms of disease-free survival or overall survival (p=0.562, p=0.149, log-rank, respectively). Low body mass index (BMI) (p<0.001), white blood cells (WBC) at baseline (p=0.008), and NAC regimen (p=0.026) significantly related with FN in all patients with breast cancer. Moreover, among patients with hormone receptor-positive/human epidermal growth factor receptor 2-positive breast cancer, low WBC (p=0.007) and low absolute lymphocyte counts (ALC) at baseline (p=0.039) were significantly associated with FN, and overall survival was significantly worse in patients with FN development (p=0.039, log-rank). Conclusion: Poor immune activity-related factors, low ALC or BMI, may be useful to predict the development of FN in patients with breast cancer.